Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 15;8(5):446-54. Unique Identifier : AIDSLINE MED/95211536
Pachl C; Todd JA; Kern DG; Sheridan PJ; Fong SJ; Stempien M; Hoo B; Besemer D; Yeghiazarian T; Irvine B; et al; Nucleic Acid Systems, Chiron Corporation, Emeryville, California; 94608, USA.

Abstract: The level of human immunodeficiency virus type 1 (HIV-1) RNA in human plasma has been quantitated directly with use of a solid-phase nucleic acid hybridization assay, based on branched DNA (bDNA) signal amplification technology with chemiluminescent detection. Signal amplification is accomplished by the incorporation of sites for 1,755 alkaline phosphatase-labeled probes per genome of HIV-1, after successive hybridization of target-specific oligonucleotides and bDNA amplifier molecules. The assay is performed in microwells, much like an immunoassay, and is amenable to routine laboratory use. Reproducibility and specificity studies indicated that the bDNA method was precise and showed no reactivity with seronegative donors. HIV-1 RNA levels were quantitated for 348 seropositive specimens, with a detection rate of 83% for those specimens from patients with < 500 CD4+ T-cell counts. Plasma RNA levels were found to change with disease stage, and in response to antiviral therapy. Quantitation of HIV-1 RNA in the plasma of HIV-1-infected patients, with use of the bDNA assay, may be a useful method for monitoring HIV-1 disease progression and therapeutic response.

Keywords: Acyclovir/THERAPEUTIC USE CD4 Lymphocyte Count Didanosine/THERAPEUTIC USE Disease Progression Drug Therapy, Combination DNA, Single-Stranded Gene Amplification Genes, pol Human HIV Seropositivity/DIAGNOSIS/DRUG THERAPY/*VIROLOGY HIV-1/*GENETICS/ISOLATION & PURIF Longitudinal Studies Nucleic Acid Hybridization Oligonucleotide Probes Reproducibility of Results RNA, Viral/*BLOOD Sensitivity and Specificity Zidovudine/THERAPEUTIC USE JOURNAL ARTICLE
950730
M9570913

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .